Abstract:8533 Background: Circulating tumor DNA (ctDNA) has emerged as a potential novel biomarker to predict molecular residue disease in lung cancer after definitive treatment. Herein, we investigated the value of ctDNA in prognosing risk of relapse and monitoring the effect of adjuvant therapy in surgical non-small cell lung cancer (NSCLC) patients. Methods: Forty-one surgical NSCLC patients were enrolled. Tumor tissues were collected at surgery and subjected to targeted NGS of 1021 cancer-related genes. The serial peripheral blood samples were collected at postoperative one month and then at every third or sixth month and subjected to ultra-deep targeted NGS covering 338 genes. Results: From 41 eligible patients including 18 patients with stage I disease, 2 with stage II and 21 with stage III, 41 tumor tissues and 137 plasma samples were enrolled and successfully tested. In tissue samples, 323 somatic variations were identified, with a median of 8 (range, 1-21) gene variations detected in each patient. TP53 was the most common mutation (63.41%), followed by EGFR (58.53%), LRP1B (17.07%) and KRAS (14.63%). The first-postoperative ctDNA positive was found in 13 of 41 patients (31.71%), 9 stage III, 2 stage II and 2 stage I. During a median 9.47 months follow-up, 38.46% (5/13) patients with detectable ctDNA in the first postoperative blood sample experienced recurrence, while 3.57% (1/28) patients with undetectable ctDNA ultimately recurred. The DFS can be stratified by the first-postoperative ctDNA status, with ctDNA-positive groups having significantly reduced DFS (p < 0.05). We detected ctDNA in at least one time point after surgery in 17 patients (41.46%), 5 of them (29.41%) experienced recurrence. Twenty-four patients without ctDNA detection during postoperative surveillance, one (4.17%) of them ultimately recurred. Serial ctDNA detection revealed disease recurrence ahead of radiologic imaging by a median of 5.25 months (range, 0.98-14.19). Among the 41 patients, 6 patients had surgery alone, 35 patients received adjuvant therapy. For these 35 patients, ctDNA analysis can stratify patients before and after adjuvant therapy. Recurrence ratio was 33.33% (4/12) in patients with detectable and 4.34% (1/23) in patients with undetectable ctDNA before adjuvant therapy. For ctDNA analysis after adjuvant therapy, no patients (11/11) with negative ctDNA had disease-recurrence while 33.33% (1/3) patients with positive ctDNA experienced recurrence. All four patients with clearance ctDNA by adjuvant therapy remained disease free. Conclusions: For NSCLC patients, postoperative ctDNA is a prognostic marker, which reveals disease recurrence ahead of radiographic examination. Importantly, ctDNA-detecting may facilitate personalized adjuvant therapy, and applying adjuvant therapy to the patients with detectable ctDNA could bring clinical benefits for them.

Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer

Clinical Utility of Tumor-Naïve Presurgical Circulating Tumor DNA Detection in Early-Stage NSCLC

Potential Utility of Methylation Levels Detected from Circulating Tumor DNA (ctdna) in Predicting Molecular Residual Disease (MRD) in Patients with Resected Non-Small Cell Lung Cancer (NSCLC).

Postoperative ctDNA detection predicts relapse but has limited effects in guiding adjuvant therapy in resectable stage I NSCLC

Detection of epidermal growth factor receptor (EGFR) mutations from preoperative circulating tumor DNA (ctDNA) as a prognostic predictor for stage I–III non-small cell lung cancer (NSCLC) patients with baseline tissue EGFR mutations

Development and clinical application of a methylated ctDNA assay in the preoperative risk classification of resectable colon cancer

Abstract 3384: Combined DNA methylation analysis in size based CTC fraction and matched plasma-cfDNA provides prognostic information in early stage NSCLC

Early Detection of Molecular Residual Disease and Risk Stratification for Stage I to III Colorectal Cancer via Circulating Tumor DNA Methylation

Dynamic ctDNA to inform the precise management of resected NSCLC: LUNGCA-2 study.

Perioperative ctDNA-Based Molecular Residual Disease Detection for Non–Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1)

Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

Postoperative ctDNA in indicating the recurrence risk and monitoring the effect of adjuvant therapy in surgical non–small cell lung cancers.

Clinical Implications of Monitoring Circulating Tumor DNA in Early- and Late-Stage Non-Small Cell Lung Cancer Patients.

Preoperative Mutational Analysis of Circulating Tumor Cells (CTCs) and Plasma-cfDNA Provides Complementary Information for Early Prediction of Relapse: A Pilot Study in Early-Stage Non-Small Cell Lung Cancer

Circulating Tumor DNA as a Prognostic Biomarker in Localized Non-small Cell Lung Cancer

Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non–small cell lung cancer

Dynamic monitoring circulating tumor DNA in plasma samples by PEAC technology for patients with early-stage non–small cell lung cancer after surgery.

Monitoring of circulating tumor DNA and its aberrant methylation in the surveillance of surgical lung Cancer patients: protocol for a prospective observational study.

Predicting pathological response to neoadjuvant immunotherapy plus chemotherapy in resectable non-small cell lung cancer through liquid biopsy.

DNA methylation analysis of tumor suppressor genes in liquid biopsy components of early stage NSCLC: a promising tool for early detection

Evaluating the Role of Methylated Circulating Tumor DNA in Combination With Pathological Prognostic Factors for Predicting Recurrence of Colorectal Cancer